Interim report January - March 2011

TURNOVER INCREASES BY 50 % AND PROFIT DOUBLES

JanuarY-MARCH 2011

  • NET SALES amounted to 23.9 million SEK (15.9).  
  • EBIT amounted to 6.8 million SEK (3.2).  
  • PROFIT AFTER TAX amounted to 5.1 million SEK (2.4).  
  • EARNINGS PER SHARE amounted to 0.55 SEK (0.26).  
  • TOTAL CASH FLOW amounted to -4.7 million SEK (1.7).  

IMPORTANT EVENTS DURING THE FIRST QUARTER:

  • Royalty proceeds from ProViva increased by 10 percent compared to the first quarter 2010.
  • Proceeds from Dietary Supplements increased by 125 percent and amounted to 8.3 million SEK (3.7).
  • New distribution agreement with Ta`am Teva Altman, Israel, regarding dietary supplements based on Lp299v .
  • Probi has repurchased 150,000 treasury shares for a value of 6.9 million SEK.

CEO’s COMMENTS:

”It is a sign of strength that we grew by 50 percent at the same time as profits doubled. 2011 was our best year ever and the positive trend continues. Our agreements with Danone and the successful launch of our own brands are two solid platforms upon which further growth can be built,” says Michael Oredsson, CEO of Probi.

The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was submitted for disclosure on 27 April 2011 at 08:45 (cet)

For further information, contact:

Michael Oredsson, CEO Probi, phone: +46 (0)46 286 89 23 or +46 (0)707 18 89 30, e-mail: michael.oredsson@probi.se

OM PROBI

Probi är en ledande aktör inom probiotisk forskning och utveckling av effektiv och väldokumenterad probiotika. Forskningsområdena är: mage och tarm, immunförsvar, metabola syndromet samt stress och återhämtning. Probis kunder är ledande företag inom segmenten functional food och kosttillskott. Totala intäkter 2010 var 81,1 miljoner SEK, varav merparten utgjordes av royaltyintäkter. Probis aktie är noterad på Nasdaq OMX Stockholm, Small Cap. Probi har cirka 4 200 aktieägare. Läs mer på www.probi.se

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links